Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial

NCT05556720 is registered in ClinicalTrials.gov with Monash University as lead sponsor.

NCT NCT05556720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05556720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial
Lead sponsor
Monash University
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 1, 2022
Completion date
December 31, 2026
Enrollment
960 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, covid-19 vaccines, hiv, lymphoma, non-hodgkin, multiple myeloma, organ transplantation